CD163 and breast carcinoma: When we analyzed pro-tumor activity of TAMs using human breast cancer tissue, we verified that high expression of the macrophage marker CD163 was significantly associated with a reduced overall survival of these breast cancer patients in multiple breast cancer datasets (Figure 7—figure supplement 1A–1D).